Key features and details
- Rabbit polyclonal to BACH1/BRIP1
- Suitable for: IP
- Reacts with: Human
- Isotype: IgG
Product nameAnti-BACH1/BRIP1 antibody
See all BACH1/BRIP1 primary antibodies
DescriptionRabbit polyclonal to BACH1/BRIP1
Tested applicationsSuitable for: IPmore details
Species reactivityReacts with: Human
Synthetic peptide within Human BACH1/BRIP1 aa 1100-1150. The exact sequence is proprietary.
Database link: Q9BX63
- IP: HeLa whole cell lysate.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7
Preservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate
pH 7 to 8
Concentration information loading...
PurityImmunogen affinity purified
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab264132 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at 1-4 µg/mg of lysate.
Use at 1-4 µg/mg of lysate.
FunctionDNA-dependent ATPase and 5' to 3' DNA helicase required for the maintenance of chromosomal stability. Acts late in the Fanconi anemia pathway, after FANCD2 ubiquitination. Involved in the repair of DNA double-strand breaks by homologous recombination in a manner that depends on its association with BRCA1.
Tissue specificityUbiquitously expressed, with highest levels in testis.
Involvement in diseaseDefects in BRIP1 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
Defects in BRIP1 are the cause of Fanconi anemia complementation group J (FANCJ) [MIM:609054]. It is a disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.
Sequence similaritiesBelongs to the DEAD box helicase family. DEAH subfamily.
Contains 1 helicase ATP-binding domain.
Domain4Fe-4S iron-sulfur-binding is required for helicase activity (PubMed:20639400).
modificationsPhosphorylated. Phosphorylation is necessary for interaction with BRCA1, and is cell-cycle regulated.
- Information by UniProt
- ATP dependent RNA helicase BRIP1 antibody
- ATP-dependent RNA helicase BRIP1 antibody
- BACH 1 antibody
BACH1/BRIP1 was immunoprecipitated from 1mg of HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate with ab264132 at 3 µg/mg lysate. Western blot was performed from the immunoprecipitate using a different antibody at 1 µg/ml.
Lane 1: ab264132 IP in HeLa whole cell lysate.
Lane 2: Control IgG.
Exposure time: 10 secs.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab264132 has not yet been referenced specifically in any publications.